Introduction {#S1}
============

A purine analog 2-chlorodeoxyadenosine (2-CdA) has been accepted as the treatment of choice in hairy cell leukemia and low-grade non-Hodgkin's lymphomas. It has also been recommended in stage IV A/B of cutaneous T-cell lymphomas (CTCL), along with chlorambucil, liposomal doxorubicin, CHOP polychemotherapy, denileukin difitox, and others.^[@R1]--[@R11]^ The aim of our study was to analyze the efficacy and side effects of 2CdA treatment for CTCL.

Materials and Methods {#S2}
=====================

We treated six CTCL patients (five with *mycosis fungoides*; four in stage IIB, one in IVB, and one with peripheral cutaneous T-cell lymphoma (PTCL), unspecified) with 2CdA (pulses of 0.12 mg/kg/day/5 days).^[@R10],[@R12]--[@R20]^ The patients failed standard therapies including glucocorticoids, retinoids, methotrexate, radiotherapy, and phototherapy. The efficacy of the treatment was established based on the clinical evaluation of skin lesions and internal involvement.

Results {#S3}
=======

The patients received 1--8 pulses of 2CdA ([Table 1](#T1){ref-type="table"}, [Figures 1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"}). One patient achieved total remission (patient 46/F, [Figure 2](#F2){ref-type="fig"}A and B), lasting six months. Partial remission was achieved in four cases. Progression of the disease during treatment appeared in one case (patient 71/F, [Figure 4](#F4){ref-type="fig"}). One patient died because of myelosupression and staphylococcal sepsis just after the second pulse with 2CdA (patient 43/F, [Figure 1](#F1){ref-type="fig"}). We tried to avoid the infections by chemoprophylaxis with co-trimoxazol and acyclovir during and after 2CdA treatment. One patient died because of progression of the lymphoma to the central nervous system a few months after the end of treatment (patient 46/F with PTCL). The other two patients achieved partial remission and required further chemotherapy ([Table 2](#T2){ref-type="table"}).

Table 1Characteristics of the patients.Age/GenderDiagnosis and stage^[@R1]^Duration of the diseasePrevious treatment43/F ([Fig. 1](#F1){ref-type="fig"})MF IIB13 mthPrednison, PUVA, RePUVA cyclofosphamid46/F ([Fig. 2](#F2){ref-type="fig"}, B)MF IVB31 mthPUVA46/FPTCL6 mthAcitretin65/F ([Fig. 3](#F3){ref-type="fig"}A, B)MF IIB6 mthacitretin, acitretin + MTX58/MMF IIB16 mthAcitretin, MTX, local electron beam therapy (Department of Radiotherapy)71/F ([Fig. 4](#F4){ref-type="fig"}A, B)MF IIB4 yrPrednisone, MTX, UVB311, acitretin, bexaroten (severe side effects: total skin peeling, bullae, and progression of the disease to MF IV)[^1]

Figure 1(A and B) Before 2CdA treatment: patient died of *S. aureus* sepsis after the second pulse.

Figure 2(A, B and C) Before 2CdA treatment; (D and E) after six pulses of 2CdA (MF mimicking *lichen planus*).

Figure 3(A) Patient 65/F before2CdA treatment; and (B) after treatment (remission but new tumors have appeared).

Figure 4(A) Patient 71/F before 2CdA treatment; and (B, C and D) after one pulse of 2CdA treatment: rapid progression just after the treatment showing *faces leonona*. This was followed by seven pulses of CHOP with only 7--10 days' lasting remission, then by TSEB.

Table 2Response to 2-chlorodeoxyadenosine.PatientNo of cycles/dose per cycle (1 cycle = 5 d)Duration of the cutaneous responseLymph node status (response)Outcome43/K ([Fig. 1](#F1){ref-type="fig"})2/0.12 mg/kg (7 mg/d)No responseSlightDeath because of *S. aureus* sepsis46/K ([Fig. 2](#F2){ref-type="fig"}A--E)8/0.12 mg/kg (7 mg/d)6 mounthTotalDeath because of dissemination of MF (6 mth after end of 2CdA)46/K3/0.12 mg/kg (8 mg/d)6 mounthTotalDeath, metastasis of lymphoma to central nervous system65/K ([Fig. 3](#F3){ref-type="fig"}A, B)6/0.12 mg/kg (7 mg/d)2 weeksModerateProgressive disease58/M6/0.12 mg/kg (13 mg/d)8 mounthNot applicableProgressive disease71/K ([Fig. 4](#F4){ref-type="fig"}A, B)1/0.12 mg/kg (7 mg/d)Progressive diseaseNot applicableProgressive disease[^2]

Discussion {#S4}
==========

2CdA therapy was mostly well tolerated in view of the known side effects ([Table 4](#T4){ref-type="table"}) although one patient died just after the second pulse because of myelosupression. The observed remissions were short-lasting. [Table 3](#T3){ref-type="table"} shows the experience with 2CdA in other centers.^[@R8],[@R13],[@R21]--[@R30]^ Based on these data, we cannot recommend 2CdA as a routine treatment of CTCL. We concluded that 2CdA is moderately effective in CTCL, giving remission in approximately 67% of patients. The remissions are very short and there is a considerable risk of fatal infections owing to immunosupression.

Table 4Dose-dependent side effects after 2-chlorodeoxyadenosine, based on data in the literature^[@R8],[@R13],[@R21]--[@R23]^Side effectTime of appearance ([\*](#TF4-1){ref-type="table-fn"})Headache (22%, 7% \>2^nd^ week)ImmediateErythema (5--27%, 10% \>2^nd^ week)EarlyNausea (0--28%)ImmediateMyelosupression (neutropenia, thrombocytopenia, lymphocytopenia)Early, distant, lateCutaneous side effects, including panniculitis (19%)ImmediateParaparesis, tetraparesis (rare)DistantHyperuricemiaImmediateRenal finction disturbances (rare)EarlyFever (46%)ImmediateFatigue (45%, 11% \>2^nd^ week)Immediate[^3]

Table 3Response to 2-chlorodeoxyadenosine in CTCL patients -- results from different centers and from the Dermatological Department, Gdansk, Poland.Number of patientsComplete (%) remissionPartial remission (%)No response (%)Bouwhius *et al.*, 2002, USA^[@R3]^6135037Kuzel *et al.*, 1996, USA^[@R12]^21141472Saven *et al.*, 1992, Canada^[@R25]^16202747Rummel *et al.*, 1998, Germany^[@R20]^6638NDNDKay *et al.*, 1992, Canada^[@R9]^402022.557.5Kong *et al.*, 1997, USA^[@R11]^24121276O'Brien *et al.*, 1994, USA^[@R23]^22182359Dept. of Dermatology, Poland (present report)6335017[^4]

[^1]: MF, *mycosis fungoides*; PTCL, primary cutaneous peripheral T-cell lymphoma.

[^2]: Response: slight, \<25%; moderate, 25--50%; significant, 50--75%; total, 100%; PTCL, primary cutaneous peripheral T-cell lymphoma.

[^3]: The time of side effects' appearance: immediate, hours; early, days, weeks; distant, weeks, months; late, months, years.

[^4]: ND, no data.
